Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial Evaluating Safety of CD19 CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)

NCT04653493 is registered in ClinicalTrials.gov with Sabz Biomedicals as lead sponsor.

NCT NCT04653493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04653493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial Evaluating Safety of CD19 CAR-T Cells in Patients With Relapsed or Refractory Acute B-cell Lymphoblastic Leukemia (R/R B-ALL)
Lead sponsor
Sabz Biomedicals
Phase
Phase 1
Overall status
Unknown status
Start date
August 31, 2021
Completion date
August 31, 2024
Enrollment
22 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

refractory b cell acute lymphoblastic leukemia (all), relapsed b cell acute lymphoblastic leukemia (all)